LIAROZOLE
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2006 (NCT00282724)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- NADPH--cytochrome P450 reductaseINHIBITOR
POR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cl.Clc1cccc(C(c2ccc3[nH]cnc3c2)n2ccnc2)c1- Mol. weight
- 345.23 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL389433 ↗
- ChEMBLCHEMBL2105595 ↗
- ChEMBLCHEMBL2105015 ↗
Also known as
- liarozole
- liarozole
- liarozole
- liarozole
- liarozole
- liarozole fumarate
- liarozole fumarate
- liarozole hcl
- liarozole hydrochloride
- liarozole monohydrochloride
- liarozole monohydrochloride
- liarozole monohydrochloride
- liarozole monohydrochloride
- liarozole monohydrochloride
- liazal
- r085246
- r 085246
- r-085246
- r 61405
- r-61405
- r 75251
- r-75251
- r-75251
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00282724 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2006 | GlaxoSmithKline, Stiefel Laboratories |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2006 |
| Stiefel Laboratories | For profit | 1 | 1 | 1 | 2006 |
2 organizations
Page 1 / 1